Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Lung Cancer. 2013 Mar;79(3):193-7. doi: 10.1016/j.lungcan.2012.12.002. Epub 2012 Dec 27.
Inherited susceptibility to lung cancer is understudied. Never smokers are an important subgroup of patients enriched for tumors harboring oncogene aberrations in the EGFR and ALK genes. We aimed to better characterize the incidence of family history of lung cancer among never smokers with NSCLC.
Clinicopathologic data, tumor genotype, family history of cancer, and specifically family history of lung cancer from 230 consecutive never smokers was retrospectively compiled and analyzed.
In our cohort, the median age was 56 years, 67% were women, 75% were white, 59% had advanced NSCLC and 87% had adenocarcinoma histology. In these tumors, 98/230 (42%) had an EGFR mutation, 17/155 (11%) had KRAS mutations and 27/127 (21%) had an ALK translocation. Family history of any cancer was common (57%) and specific family history of lung cancer was present in 42/230 cases (18%). The percentage of cases with family history of lung cancer was higher in the EGFR mutated versus EGFR wild-type NSCLCs. Out of the cases with a family history of any cancer, 22/53 (41.5%) EGFR mutated, 1/5 (20%) KRAS mutated and 3/19 (15.5%) ALK translocated cohorts had a family history of lung cancer. The ratio of family history of lung cancer to family history of cancer was significantly higher in the EGFR mutated cohort when compared to the ALK translocated plus KRAS mutated cohorts (p=0.039).
Family history of lung cancer is common in never smokers with NSCLC, and there seems to be a particular link in families in which the proband has an EGFR mutated tumor when compared to ALK translocated or KRAS mutated tumors. Further study of families with EGFR-mutated NSCLC may yield insights into the pathogenesis of this tumor type.
肺癌的遗传易感性研究较少。从不吸烟的患者是一个重要的亚组,其肿瘤富含 EGFR 和 ALK 基因中癌基因异常的患者。我们旨在更好地描述非小细胞肺癌(NSCLC)从不吸烟者的肺癌家族史发生率。
回顾性地汇编和分析了 230 例连续从不吸烟者的临床病理数据、肿瘤基因型、癌症家族史,特别是肺癌家族史。
在我们的队列中,中位年龄为 56 岁,67%为女性,75%为白人,59%为晚期 NSCLC,87%为腺癌组织学。在这些肿瘤中,98/230(42%)有 EGFR 突变,17/155(11%)有 KRAS 突变,27/127(21%)有 ALK 易位。癌症家族史很常见(57%),230 例中有 42 例(18%)有特定的肺癌家族史。有 EGFR 突变的 NSCLC 病例中,有肺癌家族史的比例高于 EGFR 野生型 NSCLC。在有癌症家族史的病例中,22/53(41.5%)的 EGFR 突变,1/5(20%)的 KRAS 突变和 3/19(15.5%)的 ALK 易位的病例有肺癌家族史。与 ALK 易位加 KRAS 突变组相比,EGFR 突变组中肺癌家族史与癌症家族史的比例显著更高(p=0.039)。
从不吸烟的 NSCLC 患者中,肺癌家族史很常见,与 ALK 易位或 KRAS 突变的肿瘤相比,在 EGFR 突变肿瘤的患者中,似乎存在家族中特定的联系。对 EGFR 突变 NSCLC 的家族进行进一步研究,可能会深入了解这种肿瘤类型的发病机制。